Research programme: IgE monoclonal antibody therapeutics - OncoQuest

Drug Profile

Research programme: IgE monoclonal antibody therapeutics - OncoQuest

Alternative Names: anti-MUC1 IgE antibody; anti-PSA monoclonal IgE; Monoclonal IgE for solid tumor immunotherapy - Quest PharmaTech

Latest Information Update: 24 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Immune Therapeutics
  • Developer OncoQuest; University of California at Los Angeles
  • Class Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; IgE receptor modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 20 Oct 2016 IgE monoclonal antibody therapeutics is still in preclinical trials for Cancer, Solid tumours and Prostate cancer in USA
  • 22 Mar 2016 IgE monoclonal antibody therapeutics licensed to Shenzhen Hepalink Pharmaceutical in China
  • 07 Nov 2013 Quest PharmaTech licenses anti-MUC1 IgE technology from Stanford University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top